Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

A new study has identified the protein ADAMTS5 as playing a crucial role in the spread of ovarian cancer cells, offering a ...

Pancreatic cancer is projected to become the second-deadliest cancer by 2030. By the time it's diagnosed, it's often ...

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...